Illumina is the largest genomics sequencing company in the world and as a result stands to benefit from the increasing demand of said services. Its recent acquisitions also help it in every way as they allow for more data storage, faster computing, and cancer research which together expand its market penetration and allow for more efficient core business operations.

Health technology/ services sector. High market cap for stability. Technical tools using for the performance analysis are average true range, momentum, MACD (moving average convergence divergence), RSI (relative strength index), support and resistance. Good price action. Leader in the sector.

Building initial portfolio based on momentum. illumina has had a weak recent performance, signaling a good short opportunity based on our strategy.

This investment follows our S&P 500 without oil and gas companies momentum strategy. It's 3 month returns are bottom 10 in our shortlist, so we will take a short position on it.

Our investment strategy consists of buying the top 10 performing stocks of the Nasdaq 100 index, and short-selling the 10 worst-performing stocks of the same index. We chose the companies based on their performance in the last 3 months. Due to a holding period of only one month, we believe that a passive strategy is more appropriate than an active strategy. The weight of each company in our portfolio will be approximately equal, which increases diversification benefits of this portfolio. We will use almost all available debt in order to benefit from the additional expected returns from leverage.

Following my portfolio strategy.